רוקחות-פרמקולוגיה

Topical Pimecrolimus Helpful in Infants With Atopic Dermatitis

Topical pimecrolimus (Elidel), a nonsteroidal anti-inflammatory medication, can control the symptoms of atopic dermatitis in infants aged 3 to 23 months without the risk of skin atrophy or systemic adverse effects, according to the results of a double-blind controlled trial reported in the August issue of the Journal of Allergy and Clinical Immunology.

“These results indicate that Elidel may offer significant therapeutic advantages over other treatment strategies in the long-term management of chronic eczema in infants and young children,” Lawrence Eichenfeld, MD, says in a news release. He is a clinical professor of pediatrics and medicine at University of California at San Diego and did not author the study. “A steroid-free therapy like Elidel provides a new alternative for this difficult-to-treat young patient group.”

 In this one-year study, 251 infants with atopic dermatitis aged three to 23 months were randomized 4:1 to a pimecrolimus-based regimen (n=204) or to conventional treatment (n=47). Although both groups used emollients for dry skin, early signs and symptoms of atopic dermatitis were treated with placebo cream or with pimecrolimus cream. Both groups were allowed to use moderately potent corticosteroids to treat flares.

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים

© ‫ e-Med
 כל הזכויות שמורות

 

התכנים המוצגים באתר זה מיועדים לאנשי צוות רפואי בלבד

אם כבר נרשמת, יש להקליד את פרטי הזיהוי שלך
עדיין לא נרשמת? באפשרותך לבצע רישום כאן
להרשמה לאתר